Since its discovery over 35 years ago, MDM2 has emerged as an attractive target for the
development of cancer therapy. MDM2's activities extend from carcinogenesis to immunity to …

The p53 protein has appropriately been named the “guardian of the genome”. In almost all
human cancers, the powerful tumor suppressor function of p53 is compromised by a variety …

A chalcogen bond is a nonclassical noncovalent interaction which can stabilise small‐
molecule crystals as well as protein structures. Here, we systematically explore the …

Identification of low-dose, low-molecular-weight, drug-like inhibitors of protein–protein
interactions (PPIs) is a challenging area of research. Despite the challenges, the therapeutic …

This review presents the last decade of studies on the synthesis of various types of small-
molecule inhibitors of the p53–Mouse double minute 2 homolog (MDM2) protein–protein …

Background: Cancer is a major global health problem with high mortality rate. Most of the
clinically used anticancer agents induce apoptosis through genotoxic stress at various …

Cancer is a leading cause of death worldwide. It initiates when cell cycle regulatory genes
lose their function either by environmental and/or by internal factors. Tumor suppressor …

We previously reported that RNF148 was involved in the ubiquitination-mediated
degradation of CHAC2. However, its molecular mechanism was not determined. In this …

WO2017197036A1 - Spirocyclic degronimers for target protein degradation - Google Patents
WO2017197036A1 - Spirocyclic degronimers for target protein degradation - Google Patents …

Protein degradation by the Ubiquitin-Proteasome System is one of the main mechanisms of
the regulation of cellular proteostasis, and the E3 ligases are the key effectors for the protein …